September 4-7, 2024 Hybrid Event soho.click/2024 SOCIETY OF HEMATOLOGIC ONCOLOGY TWELFTH ANNUAL MEETING TO DOWNLOAD THE MOBILE APP, GO TO: https://soho.click/app GO TO MOBILE APP
ISSN 2152-2650 Volume 24 Supplement 1 September 2024 CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA The Official Journal of the International Myeloma Society The Official Journal of the Society of Hematologic Oncology An Official Journal of the European Society for Medical Oncology Proceedings of the Society of Hematologic Oncology 2024 Annual Meeting In This Supplement
soho.click/2024 Society of Hematologic Oncology Twelfth Annual Meeting September 4–7, 2024 Location: Houston, Texas, USA & Virtual Venue (Hybrid Event) Organizing Committees SOHO Board of Directors Guillermo Garcia-Manero, MD, President & Chairperson of the Board Phillip Scheinberg, MD, President-Elect Jennifer Brown, MD, PhD, Immediate Past President Hagop Kantarjian, MD, Secretary Anthony H. Goldstone, CBE, FRCP, Past President Dieter Hoelzer, MD, PhD, Past President Alan List, MD, Past President Sagar Lonial, MD, FACP, Past President Susan M. O’Brien, MD, Past President Ching-Hon Pui, MD, Past President Moshe Talpaz, MD, Past President Julie Vose, MD, Board Member Janet Cesak, MBA, BS, Managing Director (non-voting) SOHO Steering Committee Hagop Kantarjian, MD, Chair Elias Anaissie, MD Renier Brentjens, MD, PhD Jennifer R. Brown, MD, PhD Sabina Chiaretti, MD, PhD Florence Cymbalista, MD, PhD Claire Dearden, BSc, MBBS, MD, FRCP, FRCPath John DiPersio, MD, PhD Guillermo Garcia-Manero, MD Sergio Giralt, MD Anthony Goldstone, CBE, FRCP, FRCPath Claire Harrison, MD, DM, FRCP, FRCPath Dieter Hoelzer, MD, PhD Sundar Jagannath, MD Rami S. Komrokji, MD Jeffrey Lancet, MD Suzanne Lentzsch, MD, PhD Alan List, MD Sagar Lonial, MD, FACP Selina Luger, MD Thomas Martin, MD María-Victoria Mateos, MD, PhD Emili Montserrat, MD Alison Moskowitz, MD Charles Mullighan, MBBS (Hons), MSc, MD Susan O’Brien, MD Ching-Hon Pui, MD Paul Richardson, MD Valeria Santini, MD Phillip Scheinberg, MD David Scheinberg, MD, PhD John Seymour, MBBS, FRACP, PhD Elizabeth Shpall, MD Eric Smith, MD, PhD Wendy Stock, MD Richard Stone, MD Moshe Talpaz, MD Julie Vose, MD, MBA
SOHO Education Committee Sagar Lonial, MD, FACP, Chair Pamela Allen, MD, MSc Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD Michael Andreeff, MD, PhD Stephen M. Ansell, MD, PhD Martha Arellano, MD Catherine Bollard, MD, MBChB Prithviraj Bose, MD Renier Brentjens, MD, PhD Jennifer R. Brown, MD, PhD Jorge E. Cortés, MD Charles Craddock, CBE, FRCP, FRCPath, Dphil, FMedSci Nick Cross, MA, PhD, FRCPath Florence Cymbalista, MD, PhD Naval Daver, MD Daniel DeAngelo, MD, PhD Michael Deininger, MD, PhD Meletios Dimopoulos, MD Angela Dispenzieri, MD Barbara Eichhorst, MD Pierre Fenaux, MD, PhD Alessandra Ferrajoli, MD Adele K. Fielding, MD, PhD Guillermo Garcia-Manero, MD Paolo Ghia, MD, PhD Sergio Giralt, MD Lucy A. Godley, MD, PhD Damian Green, MD Alex Herrera, MD Dieter Hoelzer, MD, PhD Elias Jabbour, MD Joseph Jurcic, MD Brad S. Kahl, MD Partow Kebriaei, MD Thomas Kipps, MD, PhD Rami S. Komrokji, MD Jeffrey Lancet, MD Mary Jo Lechowicz, MD Suzanne Lentzsch, MD, PhD Georg Lenz, MD Jeffrey H. Lipton, MD, PhD, FRCPC Bob Löwenberg, MD Selina Luger, MD Matthew Lunning, DO Kami J. Maddocks, MD Thomas Martin, MD John O. Mascarenhas, MD Marcela V. Maus, MD,PhD Laura Michaelis, MD Mohamad Mohty, MD, PhD Emili Montserrat, MD Franck Morschhauser, MD, PhD Alison Moskowitz, MD Loretta Nastoupil, MD Susan O’Brien, MD Owen O’Connor, MD, PhD Kristen M. O’Dwyer, MD Robert Orlowski, MD, PhD Prof. Francesco Passamonti, MD Krina K Patel, MD, MSc Uwe Platzbecker, MD Barbara Pro, MD Ching-Hon Pui, MD John Radford, MD Jerald Radich, MD Farhad Ravandi, MD Delphine Rea, MD, PhD Katy Rezvani, MD, PhD Josep-Maria Ribera, MD, PhD Gail J. Roboz, MD Valeria Santini, MD Laurie Sehn, MD, MPH John Seymour, MBBS, FRACP, PhD Bijal Shah, MD Eric Smith, MD, PhD Simona Soverini, PhD Alesandro M. Vannucchi, MD William Wierda, MD, PhD Thomas Witzig, MD Pier Luigi Zinzani, MD, PhD SOHO Publication Committee Sundar Jagannath, MD, Chair Brad S. Kahl, MD Hagop Kantarjian, MD Sagar Lonial, MD, FACP Moshe Talpaz, MD SOHO Scientific Committee Moshe Talpaz, MD, Chair Pamela Allen, MD, MSc Elias Anaissie, MD Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD Prithviraj Bose, MD Renier Brentjens, MD, PhD Hetty Carraway, MD, MBA Jorge E. Cortés, MD Charles Craddock, CBE, FRCP, FRCPath, Dphil, FMedSci Florence Cymbalista, MD, PhD Naval Daver, MD Marco Davila, MD, PhD Michael Deininger, MD, PhD Courtney D. DiNardo, MD, MSCE
Barbara Eichhorst, MD Pierre Fenaux, MD, PhD Adele K. Fielding, MD, PhD Guillermo Garcia-Manero, MD Andre Goy, MD, MS Dieter Hoelzer, MD, PhD Elias Jabbour, MD Sundar Jagannath, MD Tapan Kadia, MD Hagop Kantarjian, MD Partow Kebriaei, MD Eva Kimby, MD, PhD Rami S. Komrokji, MD Marina Konopleva, MD, PhD Mary Jo Lechowicz, MD Georg Lenz, MD Jeffrey H. Lipton, MD, PhD, FRCPC Alan List, MD Sagar Lonial, MD, FACP Thomas Martin, MD John O. Mascarenhas, MD Laura Michaelis, MD Ajay K. Nooka, MD, MPH, FACP Eric Padron, MD Uday R. Popat, MD Barbara Pro, MD Ching-Hon Pui, MD Prof. Anne Quinquenel, MD, PhD John Radford, MD Jerald Radich, MD Farhad Ravandi, MD Gail J. Roboz, MD Giuseppe Saglio, MD Laurie Sehn, MD, MPH Mikkael A. Sekeres, MD, MS Bijal Shah, MD Elizabeth Shpall, MD Simona Soverini, PhD Wendy Stock, MD Evangelos Terpos, MD, PhD Fritz Van Rhee, MD, PhD Julie Vose, MD, MBA Eunice S. Wang, MD Andrew Wei, MBBS, PhD Jason R Westin, MD William Wierda, MD, PhD Maurizio Zangari, MD Pier Luigi Zinzani, MD, PhD
Volume 24, Supplement 1 September 2024 CLINICAL LYMPHOMA, MYELOMA LEUKEMIA & Volume 24, Number 7 July 2024 Senior Editor-in-Chief Sundar Jagannath, MD New York, New York Editors-in-Chief Brad Kahl, MD St. Louis, Missouri Hagop M. Kantarjian, MD Houston, Texas Sagar Lonial, MD Atlanta, Georgia Lymphoma Associate Editors Martin Heinz Dreyling, MD München, Germany Mehdi Hamadani, MD Milwaukee, Wisconsin Matthew Lunning, MD Omaha, Nebraska Mark Roschewski, MD Bethesda, Maryland Myeloma Associate Editors Ajai Chari, MD San Francisco, California Mariateresa Fulciniti, PhD Boston, Massachusetts Morie Gertz, MD Rochester, Minnesota Amrita Krishnan, MD Duarte, California Roberto Mina, MD Torino, Italy Enrique Ocio, MD, PhD Santander, Spain Evangelos Terpos, MD, PhD Athens, Greece Leukemia Associate Editors Martha Arellano, MD Atlanta, Georgia Ali Bazarbachi, MD Beirut, Lebanon Prithviraj Bose, MD Houston, Texas Meletios A. Dimopoulos, MD Athens, Greece Pierre Fenaux, MD, PhD Bobigny, France Guillermo Garcia-Manero, MD Houston, Texas Armin Ghobadi, MD Saint Louis, Missouri Rami Komrokji, MD Tampa, Florida John Mascarenhas, MD New York, New York Susan O’Brien, MD Orange, California Ching-Hon Pui, MD Memphis, Tennessee Valeria Santini, MD Florence, Italy Moshe Talpaz, MD Ann Arbor, Michigan William G. Wierda, MD, PhD Houston, Texas JoséMaría Ribera, MD, PhD Barcelona, Spain Lymphoma Editorial Board Stefan Barta, MD, MS, MRCP Philadelphia, Pennsylvania Danielle Brander, MD Durham, North Carolina Paolo Caimi, MD Cleveland, Ohio Jonathon Cohen, MD, MS Atlanta, Georgia Alex Herrera, MD Duarte, California Brian Hill, MD, PhD Cleveland, Ohio Manali Kamdar, MD Aurora, Colorado Vaishalee Kenkre, MD Madison, Wisconsin Lale Kostakoglu Shields, MD, MPH Charlottesville, Virginia Daniel Landsburg, MD Philadelphia, Pennsylvania Neha Mehta-Shah, MD Saint Louis, Missouri Gr zegor z Nowakowski, MD Rochester, Minnesota Steven Park, MD Charlotte, North Carolina Tycel Phillips, MD Duarte, California Craig Portell, MD Charlottesville, Virginia Peter Riedell, MD Chicago, Illinois Bijal Shah, MD Tampa, Florida Jakub Svoboda, MD Philadelphia, Pennsylvania David T. Yang, MD Madison, Wisconsin Myeloma Editorial Board Meral M. Beksac, MD Ankara, Turkey Wee Joo Chng, MB ChB, PhD Singapore, Singapore Mattia D’Agostino, MD Torino, Italy Michel Delforge, MD, PhD Leuven, Belgium Hermann Einsele, MD Würzburg, Germany Efstathios Kastritis, MD Athens, Greece Xavier Leleu, MD, PhD Poitiers, France Philippe Moreau, MD Nantes, France Paola Neri, MD, PhD Calgary, Alberta, Canada Charlotte Pawlyn, PhD London, United Kingdom Rao H. Prabhala, PhD Boston, Massachusetts Hang Quach, MD Melbourne, Australia Karthik Ramasamy, MD Oxford, United Kingdom Joshua Richter, MD New York, New York Fredrik Schjesvold, MD Oslo, Norway Cyrille Touzeau, MD, PhD Nantes, France Sonja Zweegman, MD, PhD Amsterdam, Netherlands Ajay Nooka, MD Atlanta, Georgia Leukemia Editorial Board Anjali Advani, MD Cleveland, Ohio Rachid Baz, MD Tampa, Florida Naval G. Daver, MD Houston, Texas Courtney DiNardo, MD, MSCE Houston, Texas James Foran, MD, FRCP Jacksonville, Florida Carraway Hetty, MD Cleveland, Ohio Nitin Jain, MD, MSPH Houston, Texas Tapan M. Kadia, MD Houston, Texas Aaron Logan, MD, PhD San Francisco, California Abhishek Maiti, MD Houston, Texas Lucia Masarova, MD Houston, Texas Naveen Pemmaraju, MD Houston, Texas Pia Raanani, MD Petah Tikva, Israel Farhad Ravandi, MD Houston, Texas Philipe Rousselot, MD, PhD Le Chesnay, France Bijal Shah, MD Atlanta, Georgia Jamile Shammo, MD, FACP, FASCP Chicago, Illinois Eunice Wang, MD Buffalo, New York Pier Luigi Zinzani, MD Bologna, Italy Maro Ohanion, DO Houston, Texas Publisher Ande Nichols Pennsylvania, USA Index Medicus/PubMed (NLM), Journal Citation Reports/ Science Edition (Thomson ISI), Cambridge Scientific Abstracts (CSA/CIG), CINAHL: Cumulative Index to Nursing & Allied Health Literature (EBSCO), Current Contents®/ Clinical Medicine (Thomson ISI), EMBASE/Excerpta Medica (Elsevier), Science Citation Index Expanded™ (Thomson ISI), Science Citation Index® (Thomson ISI), SCOPUS (Elsevier), Web of Science® (Thomson ISI)
Volume 24, Supplement 1 September 2024 CLINICAL LYMPHOMA, MYELOMA LEUKEMIA & Volume 24, Number 7 July 2024 Clinical Lymphoma, Myeloma & Leukemia (ISSN 2152-2650) is published monthly by Elsevier, 230 Park Avenue, Suite 800, New York, NY 10169. POSTMASTER: Send address changes to Clinical Lymphoma, Myeloma & Leukemia , Elsevier Customer Ser- vice Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA. Submit online: https://www.evise.com/profile/#/CLML/login . Annual subscription rates United States and possessions: individual, $231. All other coun- tries: individual, $256. Orders, claims, and journal inquiries Please visit our Support Hub page https://service.elsevier.com for assistance . Advertising information: Advertising orders and enquiries can be sent to: USA, Canada and South America: Jaichand Ramsaroop, Advertising Sales Depart- ment, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169, USA; phone: (+1) (212) 633-3690; fax: (+1) (212) 633- 3820; e-mail: j.ramsaroop@elsevier.com. Reprints To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169; E-mail: reprints@elsevier.com. Author inquiries For inquiries relating to the submission of articles (including elec- tronic submission where available) please visit this journal’s home- page. You can track accepted articles at http://www.elsevier.com/ trackarticle and set up e-mail alerts to inform you of when an ar- ticle’s status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact de- tails for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. Funding body agreements and policies Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as spec- ified as conditions of their grant awards. To learn more about exist- ing agreements and policies please visit http://www.elsevier.com/ fundingbodies . Copyright ©2024 Elsevier Inc. All rights reserved. This journal and the individual contributions contained in it are protected under copyright, and the following terms and conditions apply to their use in addition to the terms of any Creative Commons or other user license that has been applied by the publisher to an individual article: Photocopying Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or system- atic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ( + 44) 1865 843830 (UK) / ( + 1) 215 239 3804 (USA). Derivative Works Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company. For any subscribed articles or articles published under a CC BY-NC-ND license, permis- sion of the publisher is required for all other derivative works, including compilations and translations. (please consult www.elsevier.com/permissions). Storage or Usage Except as outlined above or as set out in the relevant user license, no part of this pub- lication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Permissions For information on how to seek permission visit www.elsevier.com/permissions or call: ( + 1) 800-523-4069 x 3808 (please consult www.elsevier.com/permissions). Author rights Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at http://www.elsevier.com/authorsrights ). Notice Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher for any injury and/or damage to per- sons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the mate- rial herein. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. ∞ �The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper)
soho.click/2024 Society of Hematologic Oncology Twelfth Annual Meeting September 4–7, 2024 Location: Houston, Texas, USA & Virtual Venue (Hybrid Event) Publication of this abstract supplement is supported by the Society of Hematologic Oncology. Table of Contents Message from the Chairpersons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S1 Extended Abstracts EXABS-101-AML: Is Favorable-Risk AML Always Favorable? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3 Richard Dillon EXABS-106-LYM: Management Algorithm for Nodular Lymphocyte-Predominant Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . S5 Ryan Lynch, MD EXABS-107-LYM: Current Management of Waldenstrom Macroglobulinemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S7 Jorge J Castillo, MD EXABS-108-LYM: New Agents in Marginal Zone Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S9 Izidore S. Lossos EXABS-110-NHL: The Promise of Immunotherapies in T-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S11 Colin J Thomas, and Stefan K Barta EXABS-113-CML: Is There a Role for Combination Therapy, And If So, What Combinations? . . . . . . . . . . . . . . . . . . . . . . . . . . . . S13 Massimo Breccia EXABS-114-CML: The Pregnant or Want-to-Be Pregnant CML Patient . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S16 Elisabetta Abruzzese, Malgorzata Monika Trawinska, Martina Canichella, and Paolo de Fabritiis EXABS-116-MPN: Managing Systemic Mastocytosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S19 Jason Gotlib, MD, MS EXABS-117-MDS: MDS/MPN Overlap Syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S22 Eric Padron, MD EXABS-121-MM: Monoclonal Gammopathy of Renal Significance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S23 Nelson Leung EXABS-131-AML: AI in Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S25 Torsten Haferlach, MD, PhD EXABS-132-AML: Application of Molecular Diagnostics in Developing Countries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S27 Peter J.M. Valk
EXABS-133-ALL: Elderly ALL: Inotuzumab as Induction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S29 Matthias Stelljes EXABS-134-ALL: Development of Inotuzumab Ozogamicin and Blinatumomab for Frontline Treatment of Older Patients with Ph-Negative B-Cell Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S31 Matthew Wieduwilt, MD, PhD EXABS-135-ALL: Elderly ALL: Low-Dose Chemotherapy and Immunotherapy Combinations . . . . . . . . . . . . . . . . . . . . . . . . . . . S34 Patrice Chevallier, MD, PhD EXABS-136-LYM: Genomics in Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S37 Michael R. Green, PhD EXABS-137-LYM: Interpreting Baseline PET Metrics and PET-Based Response in Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . S39 Judith Trotman, BHB, MBChB, FRACP, FRCPA, and Sally Barrington, MD, MS EXABS-139-LYM: Management of High-Grade B-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S41 Adam J Olszewski EXABS-140-LYM: Does Limited-Stage Diffuse Large B-Cell Lymphoma (LS-DLBCL) Matter? . . . . . . . . . . . . . . . . . . . . . . . . . . . S44 Arina Martynchyk, and Eliza A Hawkes EXABS-144-CML: Atypical CML: Diagnosis and Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S47 Massimo Breccia EXABS-146-MPN: Challenging Scenarios in the Management of Myeloproliferative Neoplasms . . . . . . . . . . . . . . . . . . . . . . . . . . S49 Anand A. Patel EXABS-153-MM: The Role of Maintenance Therapy in the Treatment of Newly Diagnosed Multiple Myeloma . . . . . . . . . . . . . . . S53 Zhubin Gahvari, and Natalie Callander EXABS-154-CLL: Should We Note Subset #2-Positive Patients as a Specific Group Within Mutated or Unmutated CLL? . . . . . . . S57 Thomas Chatzikonstantinou EXABS-155-CLL: Extended Abstract: MRD as Surrogate for PFS/OS/Clinical Implications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S59 Othman Al. Sawaf EXABS-156-CLL: What Prognostic Models Should We Use in CLL? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S60 Stefano Molica, and David Allsup EXABS-159- CT: Survivorship Issues for Stem Cell Transplant and CAR T Recipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S63 Minoo Battiwalla, MD, MS EXABS-160-ALL: Asparaginase: Optimizing Efficacy and Minimizing Toxicity in Pediatric and AYA ALL/LBL . . . . . . . . . . . . . . . S64 Rachel E. Rau EXABS-161-ALL: Success of a Modified Adolescent and Young Adult Treatment for Acute Lymphoblastic Leukemia in Mexico . S67 Juan Luis Ontiveros, and Roberta Demichelis-Gómez EXABS-162-ALL: Incorporating Immunotherapy into Upfront ALL Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S71 Mark R. Litzow, MD EXABS-163-ALL: CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies . . . . . . . . . . . . . . . . . . . . . . . . . . S73 Peihua Lu EXABS-164-ALL: Transplant in Adult ALL: Who and When . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S75 Partow Kebriaei and Curtis Marcoux EXABS-165-ALL: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia can be Treated with ChemotherapyFree Regimens without Transplant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S79 Fadi G. Haddad, Hagop Kantarjian, Jayastu Senapati, Nitin Jain, Nicholas J. Short, and Elias Jabbour EXABS-168-ALL: Enhancing Precision Treatment for Childhood Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . S83 Ching-Hon Pui
EXABS-170-MDS: Progress in Lower-Risk MDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S85 Valeria Santini EXABS-182-AML: International Expansion of Modern AML Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S87 Lorena L. Figueiredo-Pontes, Fabiola Traina, Maria Isabel Ayrosa, Letícia O. Marani, Amanda Fernandes, and Eduardo M. Rego EXABS-185-CML: Choosing the Best Firstline Drug: Does Efficacy Make You Think About Cost? . . . . . . . . . . . . . . . . . . . . . . . . . S89 Fadi G. Haddad, Hagop Kantarjian, Koji Sasaki, Ghayas C. Issa, and Elias Jabbour EXABS-195-MPN: Optimizing Outcomes of Accelerated and Blast-Phase Myeloproliferative Neoplasms . . . . . . . . . . . . . . . . . . . S92 Naseema Gangat, MBBS, and Ayalew Tefferi, MD EXABS-200-MM: CART Should be Reserved for Late Relapse > 3 Lines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S95 Saad Z Usmani, MD, MBA, FACP EXABS-202-MM:TreatmentofEarlyRelapse:Non-CARTCells.................................................... S96 Ioannis Ntanasis-Stathopoulos, and Meletios A Dimopoulos EXABS-203-MM: Bispecific T-Cell Engagers: Sequencing, BCMA, GPRC5D, and Resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S98 Amrita Krishnan, MD EXABS-204-MM: MM Therapy in Resource-Constrained Including Maintenance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S100 Vania Hungria, MD, PhD EXABS-207-CLL:NovelApproachestoRichterSyndrome........................................................ S102 Isabella S Marchal, and Adam S Kittai EXABS-208-CLL: BTK Inhibitor Therapy Can be Stopped in CLL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S104 Taejun J. Yoon, and Inhye E. Ahn EXABS-214-TCL: A Clinically Relevant Overview of the Current PTCL Classification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S106 Ahmet Dogan, MD, PhD EXABS-215-TCL: Optimizing Frontline Treatment for PTCL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S108 Neha Mehta- Shah, MD, MSCI EXABS-220-IBCL: Approach to Untreated Follicular Lymphoma, Where Are We Now and Future Directions . . . . . . . . . . . . . . . S111 Brian T. Hill, MD, PhD EXABS-221-IBCL: How Should We Risk Stratify and Tailor Therapy for Relapsed/Refractory Indolent Lymphoma? . . . . . . . . . S113 Neha Akkad, and Christopher Flowers EXABS-222-IBCL: How to Implement the Administration of Bispecifics into Community Practice . . . . . . . . . . . . . . . . . . . . . . . S116 Tara M Graff, Maddie Koppin, and Jane Osterson EXABS-227-ABCL: Sequencing Therapies in Relapsed/ Refractory Large B-cell Lymphoma to Optimize the Chance of Cure . . S119 Efrat Luttwak, MD, MPH, and Gilles Salles, MD, PhD EXABS-229-ABCL: What Is Dark Zone Lymphoma and Is It Clinically Relevant? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S121 Brett Collinge, and David W. Scott EXABS-230-ABCL: Managing Burkitt Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S124 Jennifer L. Crombie EXABS-231-ABCL: Accessing Novel Therapies for Aggressive Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S127 Astrid Pavlovsky EXABS-234-MCL: Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S129 Craig A. Portell, MD EXABS-236-MCL: Accessing BTK Inhibitors and Other Novel Therapies for Mantle Cell Lymphoma: Are We All Invited to the Party? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S131 Guilherme Fleury Perini, MD, Laura Korin, MD, and Joaquin Diaz Schmidt, MD EXABS-242-CT: Gene Therapy Should Be the Cell Therapy of Choice for Sickle Cell Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . S133 Jaap Jan Boelens
EXABS-244-CT: CD19 CAR T Therapy Should be the Preferred Therapy for Richter’s Transformation . . . . . . . . . . . . . . . . . . . . S135 Nirav N. Shah EXABS-245-CLL: Allogeneic HCT Should Be the Referred Therapy for Richter’s Transformation . . . . . . . . . . . . . . . . . . . . . . . . S137 Issa F. Khouri, MD EXABS-248-AML: Next Questions: Acute Myeloid Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S139 Farhad Ravandi, MD EXABS-251-CML: Next Questions: Chronic Myeloid Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S140 Timothy Hughes EXABS-252-NQ: Next Questions in Aggressive B-cell Lymphomas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S142 Mark Roschewski EXABS-254-NQ: Next Questions in Peripheral T-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S146 Seda S. Tolu, and Barbara Pro EXABS-255-NQ: Mantle Cell Lymphoma: Next Steps . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S149 Michael Wang, MD EXABS-256-NQ: Hodgkin Lymphoma: Next Questions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S150 Alison J. Moskowitz Oral Abstracts Oral Abstract Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S153 Poster Presentations Poster Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S157 Submitted Abstracts Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S255 Acute Myeloid Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S285 ChronicLymphocyticLeukemia............................................................................. S339 ChronicMyeloidLeukemia................................................................................. S362 Myelodysplastic Syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S385 MyeloproliferativeNeoplasms............................................................................... S407 Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S444 Aggressive B-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S453 Indolent B-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S492 MantleCellLymphoma.................................................................................... S510 T-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S519 Multiple Myeloma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S529 Cellular Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S585 Indices Author Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S617 Subject Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S647
Message from the Chairpersons On behalf of the organizing committees, it is our pleasure to welcome you to the twelfth annual meeting of the Society of Hematologic Oncology (SOHO). As many of you know, SOHO was established in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies. Since that time, SOHO has grown from a membership base of 400 to more than 8,000 in 2024. Organized by its founders and world class committees, SOHO is the only society specific to this field. During the 3.5-day annual meeting, we will participate in a number of educational sessions including in-person didactic lectures, meet-theprofessor sessions, debates, plenary sessions, poster presentations, oral abstract presentations and other interactive exchanges and informal engagement experiences. As a hybrid event, all SOHO 2024 general sessions will be available for live and post-session viewing on the virtual platform. The theme of SOHO 2024 is “Translating Knowledge Worldwide” as it relates to the field of hematologic oncology. Topics will include Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, T-Cell Lymphoma, Mantle Cell Lymphoma, Aggressive B-Cell Lymphoma, Indolent B-Cell Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Multiple Myeloma and Cellular Therapy. We hope you will find the meeting productive, informative and enjoyable. We would like to thank all SOHO members, attendees and industry partners whose contributions and participation have been essential to the success of the society. With warmest regards, Guillermo Garcia-Manero, MD President & Chair, SOHO Chief, Section of Myelodysplastic Syndromes Department of Leukemia The University of Texas MD Anderson Cancer Center Hagop Kantarjian, MD Secretary, SOHO Professor and Chair Department of Leukemia The University of Texas MD Anderson Cancer Center S1
S3 EXABS-101-AML Is Favorable-Risk AML Always Favorable? Richard Dillon1,* 1King’s College, Cancer Genetics Laboratory, London. Guy’s Hospital, Tower Wing Floor 7, SE1 9RT, London, UK *Corresponding author: richard.dillon@kcl.ac.uk Keywords Acute myeloid leukaemia, risk stratification, molecular profiling, MRD monitoring Introduction The European Leukemia Network (ELN) 2022 risk stratification designates patients with NPM1 mutation (without FLT3 internal tandem duplication, ITD), core-binding factor (CBF) translocations (i.e., CBFB::MYH11 and RUNX1::RUNX1T1), and in-frame insertion-deletion mutations in the basic leucine zipper (bZIP) domain of CEBPA as favorable-risk, implying that they do not require allogeneic stem cell transplantation (alloSCT) in the first complete remission (CR1). However, many patients in the favorable-risk group still relapse and die from their disease. This session will focus on whether higher-risk patients such as these can be identified and, if so, whether they should receive a different treatment. There is accumulating evidence that within the favorable-risk AML subtypes, co-occurring molecular lesions can influence both relapse and overall survival (OS). Moreover, assessment of measurable residual disease (MRD) after treatment has been repeatedly shown to provide additional powerful prognostic information. The aim of this session is to outline how this information can be integrated to inform treatment decisions. Specifically, the session addresses the critical question of which patients in the ELN favorable-risk group should be considered candidates for alloSCT in CR1. Patients with NPM1 Mutation Patients with NPM1 mutation without FLT3 ITD or complex karyotype are currently assigned to the ELN favorable-risk group, with a note that this may change depending on post-induction MRD status. The prognostic power of NPM1 MRD has been well established by multiple large co-operative group studies, which show a much higher risk of relapse and death in patients testing NPM1 MRD-positive after induction.1-4 However, the exact thresholds and time points differ slightly between studies. There are currently no randomized data to answer the critical question of whether these patients should receive a transplant in the first remission. Non-randomized data from the ALFA0702 study2 suggested that only patients with a poor MRD response benefit from CR1 alloSCT, but this analysis was restricted to patients with FLT3 ITD. More recently, a meta-analysis of the NCRI AML17 and AML19 studies (n=737)5 showed a significant survival benefit for CR1 alloSCT in patients testing NPM1 MRD-positive in the peripheral blood by quantitative PCR after two cycles of intensive chemotherapy (3-year OS with CR1-allo 61% vs. 24% without, HR: 0.39, 95% CI: 0.24–0.64, P<0.001). In contrast, no survival benefit was seen for CR1 alloSCT in patients testing MRDnegative in the PB at the same time point (3-year OS 79% vs. 82%, HR: 0.82, 95% CI: 0.50–1.33, P=0.4). This finding held true regardless of baseline FLT3 ITD, suggesting that NPM1 MRD, rather than baseline FLT3 ITD status, should determine which patients receive a transplant. Several recent studies have suggested that co-mutations other than FLT3 ITD also influence outcomes. A recent large analysis of the NCRI trials (n=1,357)6 showed that rare NPM1 mutations as well as co-mutations in DNMT3A and WT1 were also associated with significantly worse survival. Patients with these mutations were significantly less likely to achieve MRD negativity but were significantly more likely to relapse if they did. However, a benefit for CR1 alloSCT could not be shown for MRD-negative patients in any of these subgroups. A third group of patients that are at a higher risk of relapse are those who remain MRD-positive at the end of consolidation chemotherapy. Importantly, many of these patients will not relapse. In one study, 42% either spontaneously converted to MRD negativity without additional treatment or had persistent, stable, low-level MRD.7 Therefore, these patients should not automatically receive additional therapy or CR1 alloSCT, but rather should be monitored closely for rising MRD, which reliably predicts relapse. Patients with Core-Binding Factor Translocations Both co-mutational profile and MRD response are predictive of relapse in patients with the core-binding factor fusions CBFB::MYH11 and RUNX1::RUNX1T1. There is some evidence that the MRD response captures and outweighs the impact of co-mutations. For example, in the CBF 2006 study,8 patients achieving an MRD reduction of 3-log10 from baseline had a 3-year cumulative incidence of relapse of 22% compared to 54% in those who did not achieve it. Also, MRD, but not mutational profile, retained significance in multivariable analysis. MRD did not, however, predict OS, in contrast to results from patients with RUNX1::RUNX1T1 from the German AML Study Group9 where MRD-positive patients had a reduced OS.
S4 Currently, there are no robust data to support changing treatment based or performing alloSCT based on MRD results at early time points. The risk of harming patients through over treatment must be considered because around half of patients with a poor early MRD response will not relapse, especially considering that the rate of successful salvage for patients with CBF AML after relapse is high.10 Several studies have confirmed that MRD positivity at the end of consolidation is common in patients with CBF AML and stable low-level MRD does not always predict relapse.9,11 Thresholds have been identified, above which the risk of relapse is substantially higher; however, the exact levels differ between studies. Therefore, the safest approach may be to monitor these patients carefully for clear evidence of rising MRD before intervention. This approach was followed in the UK NCRI AML19 study,12 and additional treatment and alloSCT were only performed in patients with a confirmed >1 log10 rise in MRD. Using this approach, the 3-year OS for CBF AML was >90%. Conclusion Mutational profile and MRD response are powerful prognostic factors in favorable-risk AML, but a key question has been whether and how to incorporate these into treatment decision-making, particularly whether they should influence the decision to perform CR1 alloSCT. For patients with NPM1 mutation, the evidence appears clear that patients who are MRD-positive in the blood after two cycles of intensive chemotherapy benefit from CR1 alloSCT, whereas those testing MRD-negative do not, regardless of mutational profile. For patients with CBF AML, there is no clear evidence to support CR1 alloSCT based on either mutational profile or early MRD response. Moreover, low-level expression of MRD at the end of treatment is common and not usually associated with relapse. A conservative approach to avoid overtreatment is to reserve alloSCT for patients fulfilling the ELN criteria for MRD relapse. References 1. Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011;29(19):2709-16. DOI: 10.1200/JCO.2011.35.0371. 2. Balsat M, Renneville A, Thomas X, et al. Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group. J Clin Oncol 2017;35(2):185-193. DOI: 10.1200/JCO.2016.67.1875. 3. Ivey A, Hills RK, Simpson MA, et al. Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med 2016;374(5):422-33. DOI: 10.1056/ NEJMoa1507471. 4. Kapp-Schwoerer S, Weber D, Corbacioglu A, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood 2020;136(26):3041-3050. DOI: 10.1182/blood.2020005998. 5. Othman J, Potter N, Ivey A, et al. Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission. Blood 2024. DOI: 10.1182/blood.2023023096. 6. Othman J, Potter N, Ivey A, et al. Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML. Blood 2024. DOI: 10.1182/blood.2024024310. 7. Tiong IS, Dillon R, Ivey A, et al. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Adv 2021;5(23):51075111. DOI: 10.1182/bloodadvances.2021005455. 8. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013;121(12):2213-23. DOI: 10.1182/ blood-2012-10-462879. 9. Rucker FG, Agrawal M, Corbacioglu A, et al. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood 2019;134(19):1608-1618. DOI: 10.1182/ blood.2019001425. 10. Burnett AK, Goldstone A, Hills RK, et al. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol 2013;31(10):1293-301. DOI: 10.1200/ JCO.2011.40.5977. 11. Yin JA, O’Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood 2012;120(14):282635. DOI: 10.1182/blood-2012-06-435669. 12. Russell NH, Wilhelm-Benartzi C, Othman J, et al. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. J Clin Oncol 2024;42(10):1158-1168. DOI: 10.1200/JCO.23.00943.
S5 EXABS-106-LYM Management Algorithm for Nodular Lymphocyte-Predominant Hodgkin Lymphoma Ryan Lynch, MD1,* 1Fred Hutchinson Cancer Research Center, Seattle, Washington, USA *Corresponding author: rclynch@uw.edu Keywords Nodular lymphocyte, predominant Hodgkin lymphoma Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an extremely rare lymphoid malignancy (incidence 0.1–0.2 cases per 100,000/year),1-3 affecting young patients (median age 37) with a 3:1 male predominance. For a rare cancer, there is surprising heterogeneity in disease presentation and even six different pathological subtypes.4 Historically, NLPHL was treated like classic Hodgkin lymphoma (CHL) due to the similar morphology, but over time it became apparent that there were differences in outcomes and the clinical course between these entities.3 One notable difference is the lack of CD30 expression on the malignant lymphocyte predominant (LP) cell, but in contrast to CHL, there is strong CD20 expression5 Variant NLPHL subtypes are associated with inferior outcomes with standard therapies.6 NLPHL exists on a spectrum, with aggressive variants at a higher risk of transformation to T-cell histiocyte-rich large B-cell lymphoma (TCHRLBCL), a form of non-Hodgkin lymphoma. For these reasons, there is ongoing controversy over the classification of NLPHL as a form of Hodgkin lymphoma (as opposed to a subtype of B-cell lymphoma).7 A recent international prognostic score (IPS) has been validated from a large retrospective study, which can offer guidance to oncologists and patients when making management decisions.8 Given the rarity of the disease, it is challenging to create a single, unifying treatment algorithm. All patients should be staged with PET/CT. Surgical lymph node excisions should be attempted if feasible, given the rarity of malignant cells as well as the importance of the surrounding immune infiltrates for diagnosis and subclassification. Also, transformation can be challenging to identify, making needle biopsies inadequate, especially when it is highly suspected due to imaging and/or clinical behavior. In early-stage (stage-I or stage-II) disease, one should avoid systemic therapy, if possible, to reduce overall toxicity, given the long survival regardless of the treatment selected.8,9 NLPHL is very sensitive to radiation, and durable remissions in the radiation field can be achieved with manageable doses (30–36 Gray) without the use of extended fields.10-14 There is limited pediatric data on the role of complete excision in NLPHL,15 but in general, surgical excision as a definitive treatment for limited-stage NLPHL is not recommended, reserving surgery for diagnostic purposes. Patients with asymptomatic, low-tumor burden disease may also elect for observation,9 deferring therapy until required due to size or symptoms. Systemic therapy may be required for bulky or noncontiguous stage-II disease. If chemotherapy is preferred or required in limited-stage disease, one should include rituximab and avoid the use of anthracyclines unless histologic transformation is highly suspected.16,17 Combined-modality therapy does not appear to offer additional benefit over radiation alone.18 Advanced-stage (stage-III or stage-IV) NLPHL can be managed similarly to indolent B-cell non-Hodgkin lymphomas with asymptomatic, low-tumor burden disease being observed initially.9 However, intraabdominal disease (particularly splenic involvement) can predict eventual transformation.19 Therefore, close attention to clinical behavior and serial imaging is important, and repeated biopsies may be required to identify histologic transformation. There is no single preferred systemic regimen. Single-agent rituximab is highly active in NLPHL, but responses are not durable and, therefore, would not be preferred in most patients. However, one should include rituximab as part of any combination regimen, as it has been added off-label to various combination regimens (R-CVP, R-ABVD, R-CHOP).20,21 A single-center series of R-CHOP in NLPHL showed durable efficacy and that it would be preferred in cases of known or suspected transformation.16 This disease has a long natural history, and relapses, sometimes decades after initial treatment, are common. This reflects the young age at which patients are typically diagnosed as well as the challenges in completely eradicating the malignant cells, despite the high response rates seen with primary therapy.8,9 Treatment of relapsed disease first requires repeat tissue sampling to verify the histology. Additional palliative radiation can be considered in limited recurrences without prior radiation or in sites that have not been previously radiated. Those with symptomatic advanced disease can consider additional chemotherapy The most common cause of death in NLPHL is not due to the underlying lymphoma.9 For this reason, it is important to avoid treatments with excessive toxicity and to be mindful of the risk of transformation, even if it
S6 requires additional procedures and/or biopsies in order to verify the diagnosis. References 1. Eichenauer DA, Engert A: Nodular lymphocytepredominant Hodgkin lymphoma: a unique disease deserving unique management. Hematology Am Soc Hematol Educ Program 2017:324-328, 2017 2. Nogová L, Reineke T, Eich HT, et al: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocytepredominant Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 16:1683-7, 2005 3. Nogová L, Reineke T, Brillant C, et al: Lymphocytepredominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 26:434-9, 2008 4. Fan Z, Natkunam Y, Bair E, et al: Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 27:1346-56, 2003 5. Advani RH, Horning SJ, Hoppe RT, et al: Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol 32:912-8, 2014 6. Hartmann S, Eichenauer DA, Plütschow A, et al: The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 122:4246-52; quiz 4292, 2013 7. Alaggio R, Amador C, Anagnostopoulos I, et al: The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36:1720-1748, 2022 8. Binkley MS, Flerlage JE, Savage KJ, et al: International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. J Clin Oncol:Jco2301655, 2024 9. Borchmann S, Joffe E, Moskowitz CH, et al: Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood 133:2121-2129, 2019 10. Specht L, Yahalom J, Illidge T, et al: Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854-62, 2014 11. Schlembach PJ, Wilder RB, Jones D, et al: Radiotherapy alone for lymphocyte-predominant Hodgkin’s disease. Cancer J 8:377-83, 2002 12. Eichenauer DA, Plütschow A, Fuchs M, et al: Long-Term Course of Patients With Stage IA Nodular LymphocytePredominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. J Clin Oncol 33:2857-62, 2015 13. Chen RC, Chin MS, Ng AK, et al: Early-stage, lymphocyte-predominant Hodgkin’s lymphoma: patient outcomes from a large, single-institution series with long follow-up. J Clin Oncol 28:136-41, 2010 14. Wirth A, Yuen K, Barton M, et al: Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer 104:1221-9, 2005 15. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al: Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer 110:179-85, 2007 16. Fanale MA, Cheah CY, Rich A, et al: Encouraging activity for R-CHOP in advanced stage nodular lymphocytepredominant Hodgkin lymphoma. Blood 130:472-477, 2017 17. Shankar A, Hall GW, Gorde-Grosjean S, et al: Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin’s lymphoma - an AngloFrench collaborative report. Eur J Cancer 48:1700-6, 2012 18. Binkley MS, Rauf MS, Milgrom SA, et al: Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG. Blood 135:2365-2374, 2020 19. Kenderian SS, Habermann TM, Macon WR, et al: Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood 127:1960-6, 2016 20. Gotti M, Sciarra R, Pulsoni A, et al: Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. Hemasphere 7:e837, 2023 21. Pugliese N, Picardi M, Della Pepa R, et al: RituximabContaining Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up. Cancers (Basel) 13, 2021
RkJQdWJsaXNoZXIy MTk3NTQxMg==